These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

96 related articles for article (PubMed ID: 349931)

  • 1. [Combination hemodilution and defibrinogenating therapy in chronic arterial occlusive diseases].
    Ehrly AM; Saeger-Lorenz K
    Verh Dtsch Ges Kreislaufforsch; 1977; 43():332-3. PubMed ID: 349931
    [No Abstract]   [Full Text] [Related]  

  • 2. [Hemorheologic and clinical in vitro and in vivo studies of the effectiveness of isovolemic hemodilution using Gelafusal and Infukoll M40 in patients with peripheral arterial occlusive disease].
    Pöhlmann G; Braumann A; Grohmann G
    Vasa Suppl; 1991; 32():342-4. PubMed ID: 1722914
    [No Abstract]   [Full Text] [Related]  

  • 3. Improvement of the flow properties of blood: a new therapeutical approach in occlusive arterial disease.
    Ehrly AM
    Angiology; 1976 Mar; 27(3):188-96. PubMed ID: 1078314
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Results of treatment with ancrod (Arwin) in 21 patients with chronic arterial occlusive disease].
    Rosendo A; Sala Planell E; Latorre J; Marinello J; Olba L; Rutllant ML
    Rev Clin Esp; 1982 Mar; 164(5):313-6. PubMed ID: 7100546
    [No Abstract]   [Full Text] [Related]  

  • 5. [Hemorheologic effects of hydroxyethyl starch 200/0.5, dextran 40, oxypolygelatine and full electrolyte solution over 48 hours].
    Brehme S; Keysser G; Turowski A; Schmidt HH
    Z Gesamte Inn Med; 1993 Oct; 48(10):506-10. PubMed ID: 7504854
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Therapy of chronic peripheral arterial occlusive diseases with snake venom enzyme Arwin].
    Ehrly AM
    Med Welt; 1975 Mar; 26(10):446-55. PubMed ID: 1123988
    [No Abstract]   [Full Text] [Related]  

  • 7. [Drug-induced improvement of blood flow properties. Effective principle in the treatment of arterial occlusive diseases].
    Hess H; Franke I; Jauch M
    Fortschr Med; 1973 Jun; 91(17):743-8. PubMed ID: 4577522
    [No Abstract]   [Full Text] [Related]  

  • 8. [Therapeutic defibrinogenation as conservative therapy of peripheral arterial occlusive disease. A critical analysis].
    Ernst E
    MMW Munch Med Wochenschr; 1983 Sep; 125(37):796-8. PubMed ID: 6415441
    [No Abstract]   [Full Text] [Related]  

  • 9. [Rheologic effects of normovolemic hemodilution].
    Kuznetsov NA; Aleksandrova NP; Bogdanov AE; Rogulenko RV
    Anesteziol Reanimatol; 1990; (2):18-22. PubMed ID: 1698041
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Therapeutic lowering of fibrinogen levels].
    Ernst E
    MMW Munch Med Wochenschr; 1983 May; 125(21):83-4. PubMed ID: 6410202
    [No Abstract]   [Full Text] [Related]  

  • 11. Arwin in peripheral arterial circulatory disorders: controlled multicentre trials.
    Wolf GK
    Eur J Clin Pharmacol; 1976 Mar; 09(5-6):387-92. PubMed ID: 786664
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Modified dosage scheme for the subcutaneous use of arvin in patients with chronic arterial occlusive diseases].
    Ehrly AM; Köhler HJ
    Vasa; 1976; 5(2):155-62. PubMed ID: 973426
    [No Abstract]   [Full Text] [Related]  

  • 13. Proceedings: Clinical improvement in peripheral circulation by controlled defibrinogenation.
    Dormandy JA; Goyle KB
    Br J Surg; 1976 Aug; 63(8):661-2. PubMed ID: 953495
    [No Abstract]   [Full Text] [Related]  

  • 14. Hemodilution combined with defibrinogenation.
    Böhme H; Everts B
    Bibl Haematol; 1981; (47):165-72. PubMed ID: 7039611
    [No Abstract]   [Full Text] [Related]  

  • 15. Hypervolumetric hemodilution with HES 100/0.5 10% in patients with peripheral arterial occlusive disease (Fontaine, stage II): an open clinical and pharmacological phase IV study.
    Koscielny J; Latza R; Pruss A; Kiesewetter H; Jung F; Meier C; Schimetta W
    Clin Hemorheol Microcirc; 2000; 22(1):53-65. PubMed ID: 10711822
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Hemodilution in peripheral arterial occlusive disease. Placebo controlled randomized double-blind study with hydroxyethyl starch or dextran].
    Ernst E; Kollar L; Matrai A
    Acta Med Austriaca; 1991; 18 Suppl 1():27-9. PubMed ID: 1719730
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Defibrination with the snake venom enzyme arwin in peripheral arterial obstructive disease. Possibilities and limitations (author's transl)].
    Böhme H; Schmidt P; Hüttel E
    MMW Munch Med Wochenschr; 1978 Nov; 120(45):1501-4. PubMed ID: 101819
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [A comparative study of the effects of hemodilution with dextran and fluorocarbon emulsion on the changes in blood viscosity and collateral flow during myocardial ischemia].
    Ma XL; Zhao RR; Zang YM; Wang FZ
    Yao Xue Xue Bao; 1987 Sep; 22(9):641-4. PubMed ID: 2451396
    [No Abstract]   [Full Text] [Related]  

  • 19. [Drugs for the treatment of arterial circulation disorders].
    van der Kuy A
    Ned Tijdschr Geneeskd; 1988 Apr; 132(17):788. PubMed ID: 3374665
    [No Abstract]   [Full Text] [Related]  

  • 20. Blood flow properties and walking performance in chronic arterial occlusive disease.
    Angelkort B; Spürk P; Habbaba A; Mähder M
    Angiology; 1985 May; 36(5):285-92. PubMed ID: 3896044
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.